Literature DB >> 8174438

Intrahepatic mononuclear cell populations and MHC antigen expression in patients with chronic hepatitis C [correction of B]: effect of interferon-alpha.

D H Van Thiel1, X Zhang, N Baddour, H I Wright, L Friedlander, J S Gavaler.   

Abstract

Twenty-four subjects with chronic HCV infection were treated with IFN for six months. Liver biopsies were obtained before and after therapy. The number of mononuclear cells staining for CD3, CD4, CD8, 3G8, and the number of mononuclear cells, liver cells, and bile duct cells staining for class I and II MHC antigens in the biopsies was determined. NK cells increased from 16 +/- 3 to 28 +/- 3 cells per 5 high-power fields (HFP) (P < or = 0.03). The number of bile duct cells expressing class I and II MHC Ag and liver cells expressing class II MHC Ag increased (all P < or = 0.03). The only parameter that distinguished responders from nonresponders was the number of NK cells. Following IFN withdrawal, expression of these antigens declined. Based upon these data, it is concluded that IFN treatment of HCV increases: (1) the NK cells number; (2) the expression of class I MHC Ag on bile duct cells and the expression of class II MHC Ag on liver and bile duct cells; and (3) with IFN withdrawal, these changes disappear.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8174438     DOI: 10.1007/bf02087546

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  39 in total

Review 1.  Treatment of chronic hepatitis C.

Authors:  G Hess
Journal:  J Hepatol       Date:  1991       Impact factor: 25.083

2.  Alpha-interferon and post-transfusion NANB hepatitis.

Authors:  A Craxì; V Di Marco; R Volpes; R Bruno; U Palazzo; A Maggio
Journal:  Lancet       Date:  1989-02-18       Impact factor: 79.321

Review 3.  Interferon therapy of complicated hepatitis B virus infection.

Authors:  A M Di Bisceglie
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

Review 4.  Treatment of chronic hepatitis B with interferon: experience in Asian patients.

Authors:  A S Lok; C L Lai; P C Wu; J Y Lau; E K Leung; L S Wong
Journal:  Semin Liver Dis       Date:  1989-11       Impact factor: 6.115

5.  [Treatment of hepatitis B surface antigen (HBsAg)-positive chronic hepatitis with recombinant alpha-A-interferon. Results of a phase II study].

Authors:  G Hess; C Weber; S Rossol; R Voth; N Drees; K H Meyer zum Büschenfelde
Journal:  Z Gastroenterol       Date:  1988-07       Impact factor: 2.000

6.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

7.  Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C.

Authors:  K Chayama; S Saitoh; Y Arase; K Ikeda; T Matsumoto; Y Sakai; M Kobayashi; M Unakami; T Morinaga; H Kumada
Journal:  Hepatology       Date:  1991-06       Impact factor: 17.425

8.  A controlled study of treatment with recombinant interferon alpha in chronic hepatitis B virus infection: induction and maintenance schedules.

Authors:  V Carreño; J C Porres; I Mora; J Gutiez; J A Quiroga; S Ramón y Cajal; H Oliva; C Compernolle; J Bartolomé
Journal:  Antiviral Res       Date:  1987-10       Impact factor: 5.970

9.  Changes of hepatitis B virus (HBV) markers during prolonged recombinant interferon alpha-2A treatment of chronic HBV infection.

Authors:  I Mora; J C Porres; J Bartolomé; J A Quiroga; J Gutiez; C Hernández Guio; C Bas; V Carreño
Journal:  J Hepatol       Date:  1987-02       Impact factor: 25.083

Review 10.  Immune response to hepatitis B virus proteins: relevance of the murine model.

Authors:  D R Milich
Journal:  Semin Liver Dis       Date:  1991-05       Impact factor: 6.115

View more
  6 in total

1.  Effect of interferon therapy on bile duct inflammation in hepatitis C.

Authors:  B F Banner; C Allan; L Smith; L Savas; H L Bonkovsky
Journal:  Virchows Arch       Date:  1996-07       Impact factor: 4.064

2.  Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon.

Authors:  Y Itoh; T Okanoue; S Sakamoto; K Nishioji; K Yasui; M Sakamoto; K Kashima
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

3.  Reduction of virus burden-induced splenectomy in patients with liver cirrhosis related to hepatitis C virus infection.

Authors:  Tetsuro Sekiguchi; Takeaki Nagamine; Hitoshi Takagi; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

4.  Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity.

Authors:  Kerstin Herzer; Christine S Falk; Jens Encke; Sören T Eichhorst; Axel Ulsenheimer; Barbara Seliger; Peter H Krammer
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 5.  Natural killer cells: multifaceted players with key roles in hepatitis C immunity.

Authors:  Lucy Golden-Mason; Hugo R Rosen
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

Review 6.  Control of HCV Infection by Natural Killer Cells and Macrophages.

Authors:  Hugo R Rosen; Lucy Golden-Mason
Journal:  Cold Spring Harb Perspect Med       Date:  2020-09-01       Impact factor: 5.159

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.